Brought to you by 
BI signs optogenetics deal with Circuit focused on metabolic disease
04 Sep 2015
Executive Summary
In a three-year deal, Boehringer Ingelheim GMBH and Circuit Therapeutics Inc. plan to identify drug candidates for obesity and related metabolic diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BI signs optogenetics deal with Circuit focused on metabolic disease
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice